Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in *Mycobacterium tuberculosis* isolates from Uganda

Edgar Kigozi¹,², George W. Kasule³, Kenneth Musisi³, Deus Lukoye⁴, Samuel Kyobe¹, Fred Ashaba Katabazi¹,², Eddie M. Wampande¹,⁶, Moses L. Joloba¹,²‡*, David Patrick Kateete¹,²‡*

¹ Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda, ² Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda, ³ National Tuberculosis Reference Laboratory, Kampala, Uganda, ⁴ National Tuberculosis/Leprosy Program Ministry of Health, Kampala, Uganda, ⁵ College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda

‡ These authors are joint senior authors on this work.

* dkateete@chs.mak.ac.ug (DPK); moses.joloba@case.edu (MLJ)

Abstract

Background

Accurate diagnosis of tuberculosis, especially by using rapid molecular assays, can reduce transmission of drug resistant tuberculosis in communities. However, the frequency of resistance conferring mutations varies with geographic location of *Mycobacterium tuberculosis*, and this affects the efficiency of rapid molecular assays in detecting resistance. This has created need for characterizing drug resistant isolates from different settings to investigate frequencies of resistance conferring mutations. Here, we describe the prevalence and patterns of rifampicin- and isoniazid- resistance conferring mutations in isolates from Uganda, which could be useful in the management of MDR-TB patients in Uganda and other countries in sub-Saharan Africa.

Results

Ninety seven *M. tuberculosis* isolates were characterized, of which 38 were MDR, seven rifampicin-resistant, 12 isoniazid-mono-resistant, and 40 susceptible to rifampicin and isoniazid. Sequence analysis of the *rpoB* rifampicin-resistance determining region (*rpoB*RRDR) revealed mutations in six codons: 588, 531, 526, 516, 513, and 511, of which Ser531Leu was the most frequent (40%, 18/45). Overall, the three mutations (Ser531Leu, His526Tyr, Asp516Tyr) frequently associated with rifampicin-resistance occurred in 76% of the rifampicin resistant isolates while 18% (8/45) of the rifampicin-resistant isolates lacked mutations in *rpoB*RRDR. Furthermore, sequence analysis of *katG* and *inhA* gene promoter revealed mainly the Ser315Thr (76%, 38/50) and C(-15)T (8%, 4/50) mutations, respectively. These two mutations combined, which are frequently associated with isoniazid-resistance,
occurred in 88% of the isoniazid resistant isolates. However, 20% (10/50) of the isoniazid-resistant isolates lacked mutations both in \textit{katG} and \textit{inhA} gene promoter. The sensitivity of sequence analysis of \textit{rpoB}/RRDR for rifampicin-resistance via detection of high confidence mutations (Ser531Leu, His526Tyr, Asp516Tyr) was 81%, while it was 77% for analysis of \textit{katG} and \textit{inhA} gene promoter to detect isoniazid-resistance via detection of high confidence mutations (Ser315Thr, C(-15)T, T(-8)C). Furthermore, considering the circulating TB genotypes in Uganda, the isoniazid-resistance conferring mutations were more frequent in \textit{M. tuberculosis} lineage 4/sub-lineage Uganda, perhaps explaining why this genotype is weakly associated with MDR-TB.

**Conclusion**

Sequence analysis of \textit{rpoB}/RRDR, \textit{katG} and \textit{inhA} gene promoter is useful in detecting rifampicin/isoniazid resistant \textit{M. tuberculosis} isolates in Uganda however, about $\leq$20% of the resistant isolates lack known resistance-conferring mutations hence rapid molecular assays may not detect them as resistant.

**Introduction**

Tuberculosis (TB) is a disease of global public health importance declared the deadliest infectious disease alongside HIV/AIDS [1–3]. Although new cases have been reducing every year [3, 4], TB has persisted in human populations and it remains among the top 10 causes of death worldwide [3, 4]. In 2014 there were 9.6 million TB cases reported and 1.5 million deaths; more than 95% of the deaths occurred in developing countries [3, 5].

TB control programs in many countries rely on rapid identification of cases for effective treatment of the disease. Importantly, the drug-resistant forms of TB require accurate diagnosis of the type of resistance to guide therapy and interrupt transmission of resistant organisms in communities [6]. However, the conventional culture-based diagnostics for TB are slow, labor intensive and expensive, and they are often not available in the developing countries. The demand for rapid TB diagnostics led to the development and introduction of commercial molecular tests into practice. Two commonly used tests in Uganda are the “Xpert MTB/RIF” (GeneXpert, Cepheid Inc.), which diagnoses TB and detects rifampicin resistance [7–11], and the GenoType MTBDRplus (line probe assay [LPA] from Hain Life Sciences Nehren, Germany), which detects \textit{Mycobacterium tuberculosis} and its resistance to both rifampicin and isoniazid [12–14]. Rifampicin and isoniazid are the most important anti-tuberculosis drugs, and resistance to both drugs is commonly referred to as “multidrug resistance” (MDR-TB) [1]. Importantly, although the commercial molecular tests rapidly and accurately diagnose TB [15, 16], they may not detect all the resistance especially in strains with novel or unknown resistance mechanisms. The molecular tests are also ineffective at detecting heteroresistance (“the occurrence of populations of both drug-susceptible and drug-resistant isolates within the same clinical sample” [17]) due to mixed-strain TB infections. This has led to reports of varying efficiencies in the performance of rapid molecular tests in detecting drug resistance, depending on the drug in question [6, 18], or location of the strains under study. Without doubt, differences in geographical distribution of TB strains (i.e. \textit{M. tuberculosis} lineages and/or sub-lineages/genotypes) across continents [6, 18–21] significantly affect the performance of rapid molecular tests [22–24].
Molecular tests for TB target spontaneous point mutations in specific genes and/or loci in the *M. tuberculosis* chromosome that are associated with drug resistance [25], and only a limited number of mutations accounts for majority of the resistance to anti-TB drugs [6, 18]. Rifampicin-resistance, which is the best understood of all anti-TB drugs, is associated with mutations in an 81 base pair region of the *rpoB* gene commonly referred to as the rifampicin-resistance determining region (*rpoB*/RRDR). Mutations within the *rpoB*/RRDR confer resistance to rifampicin in majority of the rifampicin-resistant isolates [6], and three key mutations i.e. Ser531Leu, His526Tyr, and Asp516Val are reported to be predominant worldwide [6, 26, 27]. For isoniazid, mutations mainly in *katG* and *inhA* gene promoter, and infrequently *ahpC*, *oxyR*, *kasA*, *furA* and *ndh* genes, confer resistance to the drug [6, 18]. Approx. 64% of the phenotypic resistance to isoniazid globally is attributed to the *katG*/Ser315Thr mutation [18].

Regional variation in the frequencies of rifampicin and isoniazid resistance-conferring mutations has been reported and this could limit the sensitivity of molecular tests in detecting resistance [6, 18]. As such, it is becoming increasingly clear that the performance of rapid molecular tests in TB cannot be extrapolated from one setting to another, but needs to be validated in each geographic setting [23, 24], through systematic surveys to ascertain the mutation profiles and frequencies in geographic regions where the tests are being deployed [6, 18, 20]. It is through such investigations that the performance of new genotypic tests for TB in particular settings can be assessed. DNA sequencing is presumed to be the most appropriate approach for elucidating the patterns and frequencies of resistance conferring mutations in *M. tuberculosis*, and hence, evaluating the performance of new genotypic tests for TB [6].

Here, we describe the frequencies, patterns and distribution of rifampicin/isoniazid-resistance conferring mutations in MDR-TB isolates from Uganda based on sequence analysis of the *rpoB*/RRDR, *katG* and *inhA* gene promoter. We demonstrate that sequence analysis of those fragments is useful in detecting rifampicin- and isoniazid-resistance in Uganda however, a significant number of MDR-TB isolates lacks known resistance-conferring mutations implying that rapid molecular assays will miss detecting them as resistant to the drug in question. Also, we describe key associations between the circulating *M. tuberculosis* genotypes and occurrence of rifampicin/isoniazid resistance conferring mutations, providing new insight as to why the predominant TB strain in Uganda is weakly associated with MDR-TB.

## Results

### Frequency of *M. tuberculosis* genotypes

We investigated 38 MDR-TB isolates, seven rifampicin-resistant isolates (based on GeneXpert data hence, potentially MDR-TB isolates), and 12 isoniazid mono-resistant isolates. Additionally, 40 isolates fully susceptible to both rifampicin and isoniazid were also investigated. Altogether, a total of 97 non-repetitive isolates were studied (one isolate per TB patient) and a control strain (H37Rv). S1 Table describes the characteristics of rifampicin and isoniazid resistant isolates investigated, while S1 Fig summarizes their genotypes (lineages/sub-lineages).

**Rifampicin resistant isolates.** Of the 45 rifampicin-resistant isolates, 69% (31/45) were *M. tuberculosis* lineage 4 (Euro-American), 24% (11/45) *M. tuberculosis* lineage 3 (East-African-Indian), and 7% (3/45) *M. tuberculosis* lineage 2 (East-Asian). The most prevalent sub-lineage among lineage 4 isolates was *M. tuberculosis* sub-lineage Uganda at 52% (16/31) with 35% (11/31) of these being sub-lineage Uganda II while 16% (5/31) were sub-lineage Uganda I. Altogether, lineage 4/sub-lineage Uganda accounted for 36% (16/45) of the rifampicin-resistant isolates with 24% (11/45) being Uganda II and 11% (5/45) Uganda I. The remaining sub-lineages combined accounted for 64% (29/45) of the rifampicin-resistant isolates and they included lineage 3/sub-lineage Delhi/CAS (24%, 11/45), lineage 2/sub-lineage Beijing (7%, 3/
45), and lineage 4/sub-lineages LAM (11%, 5/45), Haarlem (11%, 5/45), Ghana (1/45, 2%), S (1/45, 2%), URAL (1/45, 2%), NEW-1 (1/45, 2%), and TUR (1/45, 2%), S1 Table and S1 Fig.

**Isoniazid resistant isolates.** Of the 50 isoniazid-resistant isolates, 72% (36/50) were M. tuberculosis lineage 4, 14% (7/50) M. tuberculosis lineage 3, and 14% (7/50) M. tuberculosis lineage 2. Similarly, the most prevalent sub-lineage among lineage 4 strains was M. tuberculosis sub-lineage Uganda at 56% (20/36), 47% (17/36) of which were Uganda II while 8% (3/36) were Uganda I. Overall, the predominant lineage 4/sub-lineage Uganda accounted for 40% (20/50) of the isoniazid-resistant isolates with 34% (17/50) being Uganda II and 6% (3/50) Uganda I. The remaining sub-lineages combined accounted for 60% (30/50) of the isolates and they included lineage 3/sub-lineage Delhi/CAS (14%, 7/50), lineage 2/sub-lineage Beijing (14%, 7/50), and lineage 4 sub/lineages LAM (10%, 5/50), Haarlem (10%, 5/50), Ghana (4%, 2/50), S (1/50, 2%), URAL (1/50, 2%), NEW-1 (1/50, 2%), and TUR (1/50, 2%), S1 Table and S1 Fig.

**Frequency of rifampicin- and isoniazid-resistance conferring mutations**

**rpoB and rifampicin-resistance.** Sequence analysis of the rpoB/RRDR revealed mutations in six codons namely 588, 531, 526, 516, 513, and 511. The most frequent mutation was Ser531Leu (40%, 18/45), while the second most frequent mutations affected codon 526 (27%, 12/45) with various non-synonymous mutations i.e. His526Asp (6 isolates), His526Tyr (3 isolates), His526Arg (1 isolate), His526Gly (1 isolate), and His526Leu (1 isolate). The third most frequent mutation was Asp516Tyr (9%, 4/45) while the infrequent mutations were Leu511Pro (4%, 2/45), Glu588Gly (2%, 1/45), and Glu513Lys (2%, 1/45), Table 1 and S1 Table.

Overall, mutations affecting three codons 531, 526, and 516, which have been reported to be responsible for up to 90% of rifampicin-resistance in most settings, accounted for only 76% of the rifampicin-resistant isolates investigated. One isolate was a double mutant as it possessed both Asp516Val and Glu588Gly mutations, S1 Table. Interestingly, 18% (8/45) of the rifampicin-resistant isolates lacked mutations in the rpoB/RRDR, Table 1 and S1 Table. These isolates were subjected to the Genotype MTBDRplus assay as an extra quality control measure but still, we did not detect resistance conferring mutations in the rpoB/RRDR of those isolates.

**katG/inhA gene promoter and isoniazid resistance.** Sequence analysis of katG gene revealed Ser315Thr mutation as the most frequent at 76% (38/50) in isoniazid-resistant isolates (Table 1), and two of these isolates possessed both Ser315Thr and Asp406Ala (S1 Table). Furthermore, six mutations were identified in the inhA gene promoter namely C(-15)T (8%, 4/50), T(-8)C (4%, 2/50), A(-255)C (2%, 1/50), G(-116)A (2%, 1/50), A(-7)C (2%, 1/50), and C(-305)T (2%, 1/50). Overall, mutations in katG and the inhA gene promoter that are frequently associated with isoniazid-resistance in most settings [i.e. Ser315Thr and C(-15)T & T(-8)C, respectively] accounted for 88% of isoniazid-resistance, with katG/Ser315Thr alone accounting for 76% of the resistance. Nevertheless, 20% (10/50) of the isoniazid-resistant isolates lacked mutations in katG and inhA gene promoter, Table 1. These isolates were also re-tested with the Genotype MTBDRplus assay as an extra quality control measure and we confirmed absence of known isoniazid-resistance conferring mutations in those isolates. All the rifampicin- and isoniazid-resistant isolates that lacked resistance conferring mutations were MDR however, none of them simultaneously lacked mutations to both drugs, S1 Table.

**No resistance conferring mutations in drug susceptible isolates.** All the 40 isolates that were susceptible to rifampicin and isoniazid did not possess resistance conferring mutations in similar genes/loci analysed, implying that drug susceptible TB isolates in Uganda do not harbour mutations associated with resistance to rifampicin and isoniazid. Furthermore, the association between phenotypic rifampicin/isoniazid-resistance and Sanger DNA sequencing data...
was evaluated to determine the sensitivity of detecting rifampicin/isoniazid-resistance based on identification of high confidence resistance-conferring mutations. For rifampicin-resistance, the sensitivity of sequence analysis of \textit{rpoB}/RRDR for the three mutations Ser531Leu, His526Tyr and Asp516Tyr was 81\% (95\%CI: 65.88\%-91.40\%). For isoniazid-resistance, the sensitivity of sequence analysis of both \textit{katG} and \textit{inhA} gene promoter for mutations Ser315Thr & C(-15)T and T(-8)C respectively, was 77\% (95\%CI: 63.16\%-87.47\%).

**Frequency of resistance conferring mutations in the circulating strains.** Of the 18 rifampicin-resistant isolates that had the most frequent high confidence mutation \textit{rpoB}/Ser531Leu, six (33\%, 6/18) were lineage 3/sub-lineage Delhi/CASI and five (28\%, 5/18) lineage 4/sub-lineage Uganda; the remaining seven isolates with the mutation \textit{rpoB}/Ser531Leu were lineage 4/sub-lineage LAM (22\%, 4/18) and lineage 2/sub-lineage Beijing (17\%, 3/18), Table 2. Additionally, isolates that carried the two other commonly occurring high confidence for rifampicin-resistance (i.e. His526Tyr, Asp516Tyr) were lineage 3/sub-lineage Delhi/CASI, and lineage 4/sub-lines TUR, URAL, and Haarlem. Though, three lineage 4/sub-lineage Uganda II isolates possessed His526Asp while a double mutant with Asp516Val and Glu588Gly was a Uganda II genotype isolate, Table 2.

---

### Table 1. Frequency and patterns of resistance conferring mutations in \textit{M. tuberculosis} isolates that were resistant to rifampicin (n = 45) and isoniazid (n = 50).

| Drug          | Locus | Mutation*                  | Frequency (No. of Isolates) | Relative Frequency\(^b\) (%) |
|---------------|-------|-----------------------------|----------------------------|-------------------------------|
| RIFAMPICIN    | \textit{rpoB} | Ser531Leu                  | 18                         | 18/45 (40)                    |
|               |       | His526X\(^c\)              | 12                         | 12/45 (27)                    |
|               | Any of Ser531Leu, His526Tyr or Asp516Tyr | Asp516Tyr                  | 04                         | 4/45 (9)                      |
|               |       | Leu511Pro                   | 02                         | 2/45 (4)                      |
|               |       | Glu513Lys                   | 01                         | 1/45 (2)                      |
|               |       | Glu588Gly                   | 01                         | 1/45 (2)                      |
|               |       | No mutation in \textit{rpoB} | 08                         | 8/45 (18)                     |
|               | Ser315Thr                  |                            | 38                         | 38/50 (76)                    |
|               | \textit{katG}              | Any of Ser315Thr, C(-15)T or T(-8)C | 40                         | 40/50 (80)                    |
|               |       | Ser315Thr+any mutation in \textit{inhA} gene promoter | 06                         | 06/50 (12)                    |
|               |       | No mutation in \textit{katG} | 08                         | 08/50 (16)                    |
|               |       | Any mutation in \textit{inhA} gene promoter | 02 [with C(-8)A or C(-15)T] | 02/50 (4)                     |
|               | C(-15)T + Ser315Thr         |                            | 04                         | 04/50 (8)                     |
|               |       | C(-15)T                    | 04                         | 4/50 (8)                      |
| ISONIAZID     | \textit{inhA} gene promoter | A(-7)C                     | 02                         | 2/50 (4)                      |
|               |       | G(-116)A                   | 01                         | 1/50 (2)                      |
|               |       | A(-255)C                   | 01                         | 1/50 (2)                      |
|               |       | C(-305)T                   | 1 (occurred in isolate with G (-116)A) | 1/50 (2)                     |
|               |       | No mutation in \textit{inhA} | 42                         | 42/50 (84)                    |
|               |       | No mutation both in \textit{inhA} & \textit{katG} | 10                         | 10/50 (20)                    |

\(^a\)We used the Escherichia coli codon numbering for \textit{rpoB} mutations

\(^b\)Compared with the total number of isolates resistant to drug of interest see Campbell et al (2011) \[6\]

\(^c\)Mutations affecting the 526 codon included His526Asp (6 isolates), His526Tyr (3 isolates), His526Arg (1 isolate), His526Gly (1 isolate), and His526Leu (1 isolate).

https://doi.org/10.1371/journal.pone.0198091.t001
Furthermore, of the 38 isoniazid-resistant isolates with the prevalent $katG/$Ser315Thr mutation, 12 (32%) were lineage 4/sub-lineage Uganda, of which seven were Uganda II (18%) and five Uganda I (13%). The remaining $katG/$Ser315Thr mutations were distributed as follows: 16% (6/38) each in lineage 4/sub-lineage Haarlem and lineage 2/sub-lineage Beijing; 13% (5/38) in lineage 3/sub-lineage Delhi/CAS, and 3% (1/38) each in lineage 4 sub-lineages S, Ghana, URAL, and NEW-1. Additionally, two isolates with $katG/$Asp406Ala mutation were lineage 4/sub-lineage NEW-1 and lineage 2/sub-lineage Beijing strains, S1 Table. Overall, $katG$ mutations were most frequent in sub-lineage Uganda strains at 30% (12/50), followed by sub-lineages Beijing (12%, 6/50), Haarlem (12%, 6/50), LAM (10%, 5/50), and Delhi/CAS (10%, 5/50). Additionally, three of the four isoniazid-resistant isolates with the $inhA$ gene promoter mutation C(-15)T were sub-lineage Uganda; likewise, one of the two isolates with the mutation T

Table 2. Frequency of rifampicin/isoniazid-resistance conferring mutations in the circulating $M. tuberculosis$ genotypes/sub-lineages in Uganda (2009–2011).

|                      | Uganda I | Uganda II | Delhi/CAS | Ghana | Beijing | LAM | NEW-1 | Haarlem | URAL | TUR | S | Sub-total |
|----------------------|----------|-----------|-----------|-------|---------|-----|-------|---------|------|-----|---|-----------|
| **Rifampicin resistance** |          |           |           |       |         |     |       |         |      |     |   |           |
| Ser531Leu            | 2        | 3         | 6         | -     | 3       | 4   | -     | -       | -    | -   | - | 18        |
| His526Asp            | -        | 3         | 1         | -     | -       | -   | 1     | 1       | -    | -   | - | 06        |
| His526Tyr            | -        | -         | 1         | -     | -       | -   | -     | -       | -    | 1   | 1 | 03        |
| Asp516Tyr            | -        | -         | -         | -     | -       | -   | -     | 3       | -    | -   | - | 03        |
| Leu511Pro            | -        | -         | 2         | -     | -       | -   | -     | -       | -    | -   | - | 02        |
| Asp516Val & Glu588Gly| -        | 1         | -         | -     | -       | -   | -     | -       | -    | -   | - | 01        |
| Glu513Lys            | 1        | -         | -         | -     | -       | -   | -     | -       | -    | -   | - | 01        |
| His526Arg            | -        | -         | -         | -     | -       | -   | -     | 1       | -    | -   | - | 01        |
| His526Leu            | -        | -         | 1         | -     | -       | -   | -     | -       | -    | -   | - | 01        |
| His526Gly            | -        | -         | -         | -     | -       | -   | -     | -       | -    | -   | - | 01        |
| No mutation           | 2        | 4         | -         | 1     | -       | -   | -     | -       | -    | -   | - | 08        |
| **Sub-total**         | 3        | 7         | 11        | 3     | 5       | 1   | 5     | 1       | 1    | -   | - | 45        |
| **Isoniazid resistance** |          |           |           |       |         |     |       |         |      |     |   |           |
| $katG$ mutations      |          |           |           |       |         |     |       |         |      |     |   |           |
| Ser315Thr            | 5        | 7         | 5         | 1     | 6       | 5   | 1     | 6       | 1    | -   | - | 38        |
| Ser315Thr + Asp406Ala| -        | 1         | -         | -     | 1       | -   | 1     | -       | -    | -   | - | 03        |
| Ser315Thr + Insertion*| -        | 1         | -         | -     | -       | -   | -     | -       | -    | -   | - | 01        |
| Ser315Thr + Asp296Glu | -        | 1         | -         | -     | -       | -   | -     | -       | -    | -   | - | 01        |
| **Sub-total (per sub-lineage)** | 5 | 7 | 5 | 1 | 6 | 5 | 1 | 6 | 1 | - | - | 38 |
| No mutation           | -        | 6         | 2         | 1     | -       | 2   | -     | -       | -    | -   | - | 12        |
| **Sub-total**         | 3        | 7         | 11        | 3     | 5       | 1   | 5     | 1       | 1    | -   | - | 50        |
| **inhA promoter**     |          |           |           |       |         |     |       |         |      |     |   |           |
| C(-15)T              | 1        | 2         | 1         | -     | -       | -   | -     | -       | -    | -   | - | 04        |
| C(-8)T               | -        | 1         | -         | -     | 1       | -   | -     | -       | -    | -   | - | 02        |
| A(-255)C             | -        | -         | -         | -     | -       | -   | 1     | -       | -    | -   | - | 01        |
| G(-116)A             | -        | -         | -         | 1     | -       | -   | -     | -       | -    | -   | - | 01        |
| A(-7)C               | -        | -         | -         | -     | 1       | -   | -     | -       | -    | -   | - | 01        |
| C(-8)A               | -        | -         | -         | -     | 1       | -   | -     | -       | -    | -   | - | 01        |
| **Sub-total**         | 2        | 2         | 1         | -     | 4       | -   | -     | -       | -    | -   | - | 42        |
| **No mutation**       | -        | -         | -         | -     | -       | -   | -     | -       | -    | -   | - |           |

*Frame shift mutation; insertion of Adenine at nucleotide position 845 of the $katG$ gene

https://doi.org/10.1371/journal.pone.0198091.t002
(-8)C was sub-lineage Uganda while the other was sub-lineage Beijing, S1 Table. The rare inhA gene promoter mutations A(-7)C, G(-116)A, & A(-255)C occurred in sub-lineages Beijing and LAM, respectively, Table 2.

Overall, the high confidence mutations for isoniazid-resistance (i.e. Ser315Thr, C(-15)T, T (-8)C) were more frequent than the high confidence mutations for rifampicin-resistance (i.e. Ser531Leu, His526Tyr, Asp516Tyr) in isolates with a genetic background of “M. tuberculosis Uganda” (P = 0.0298), S1 Table, perhaps explaining its weak association with MDR-TB. The other statistically significant associations between occurrence of resistance conferring mutations and the circulating M. tuberculosis genotypes in Uganda were (a) rpoB/Ser531Leu mutation being more prevalent in lineages 2 and 3 combined compared to lineage 4 strains (P = 0.0251), and (b) isoniazid-resistance conferring mutations Ser315Thr, C(-15)T, and C(-8) T being more prevalent in lineage 4 strains compared to lineage 2 strains (P = 0.0418), S1 Table. All the other noticed differences in association between occurrence of resistance-conferring mutations vis-à-vis circulating TB lineages/sub-lineages were not statistically significant, S1 Table.

Discussion

In this study, we have demonstrated that sequence analysis of rpoB/RRDR, katG and inhA gene promoter is useful for the detection of rifampicin- and isoniazid-resistant M. tuberculosis isolates in Uganda. Indeed, all the susceptible isolates investigated lacked resistance conferring mutations implying that drug susceptible M. tuberculosis isolates in Uganda do not harbour mutations associated with resistance to rifampicin and isoniazid, although susceptible strains with these mutations do occur in other settings [6]. Importantly, we have shown that certain M. tuberculosis clinical isolates in Uganda are phenotypically resistant to rifampicin or isoniazid, but lack high confidence resistance-conferring mutations; these isolates do occur in Uganda at significantly high rates implying that rapid molecular tests like the Xpert MTB/RIF and Genotype MTBDRplus will not detect them as resistant. Also, we have shown that a comparatively low frequency of high confidence mutations for rifampicin-resistance in M. tuberculosis sub-lineage Uganda strains that are predominant in Uganda explains the previously reported weak association between MDR-TB and M. tuberculosis Uganda genotype [28, 29].

Among the 45 rifampicin-resistant isolates investigated, Ser531Leu was the most frequent mutation (40%). This mutation was previously reported at 70% prevalence by an earlier study in Uganda [20] that investigated ≤10 rifampicin-resistant isolates, and at 58% prevalence by another study in Uganda that investigated Xpert/MTB RIF data [7]. Although our findings agree with several other studies that reported predominance of Ser531Leu in rifampicin resistant M. tuberculosis isolates (e.g. 67.2% in Georgia [30] and Mexico [31], 58% Pakistan [32], 71% Germany [33], 59% Italy [34], 56% Greece [35], and 43% Japan [36], rates for Ser531Leu in Uganda are somewhat low, and confirm a previous prevalence of 41% (21/51) for this mutation in a study that used whole genome sequencing to investigate transmission of MDR-TB at Mulago National Referral Hospital in Kampala Uganda [37]. Overall, mutations affecting the three codons 531, 526 and 516 combined, which are frequently associated with rifampicin-resistance in most settings, accounted for 76% of the rifampicin resistance in this study. The second most frequent mutation His526Asp, accounted for 13% of the rifampicin resistant isolates. This mutation was previously reported in Uganda [13, 20] though at a lower frequency. Indeed, codon 526 in rpoB/RRDR of rifampicin resistant isolates in this study possessed several non-synonymous mutations i.e. His526Asp (6 isolates), His526Tyr (3 isolates), His526Arg (1 isolate), His526Gly (1 isolate), and His526Leu (1 isolate). Our findings for codon 526 are in agreement with the findings of Clarke et al (2013), who also reported diverse mutations at
codon 526 i.e. His526Asp (3 isolates), His526Arg (1 isolate), His526Tyr (2 isolates), and His526Asn (1 isolate) [37] in MDR-TB isolates at Mulago Hospital. His526Tyr is a well-documented high confidence mutation for rifampicin-resistance in several settings, alongside Ser531Leu and Asp516Val [6, 25]. Overall, there is variation in frequencies of mutations at codon 526 (especially His526Tyr vs. His526Asp) in rifampicin resistant M. tuberculosis isolates from various settings, and we have shown that His526Asp is comparatively more frequent in isolates from Uganda. Note, some of the identified mutations at codon 526 e.g. His526Leu had not been reported before in isolates from Uganda.

Furthermore, only four (8.9%, 4/45) rifampicin-resistant isolates possessed Asp516Tyr, the third most frequent high confidence mutation for rifampicin-resistance; again, our findings are comparable with Clarke et al (2013) who reported five (9.8%, 5/51) MDR-TB isolates with mutations at codon 516 at Mulago Hospital [37]. The Asp516Tyr mutation was previously described by other investigators in Uganda [13, 20], also at low frequencies. Three isolates with Asp516Tyr were lineage 4/sub-lineage Haarlem strains, in accordance with previous reports from Spain [38]. Importantly, an isolate with the Asp516Val mutation also had Glu588Gly (double mutant); Glu588Gly has not been reported before in Uganda but was documented elsewhere in a survey that compared INNO-LiPA and MTBDRplus tests for identification of rpoB point mutations [39]. Another lineage 4/sub-lineage Haarlem isolate possessed His526Gly, a unique mutation given that it is generated by substitution of two bases at nucleotide positions 1333 and 1334. This mutation has not been reported in many settings including Uganda though it was previously associated with rifampicin-resistance [40]. Furthermore, two isolates had Leu511Pro, a mutation that was previously reported to occur in rifampicin-resistant M. tuberculosis from Uganda at 8% prevalence [7]. Elsewhere, Leu511Pro was designated a high confidence mutation in rifampicin resistant M. tuberculosis [41], and it has been reported among rifampicin resistant M. tuberculosis isolates in the UK [42].

For isoniazid, only 38 (76%) of the resistant isolates possessed the katG/Ser315Thr mutation, a finding comparable with reports from many settings worldwide [6, 18] including Mulago National Referral Hospital in Kampala i.e. 58.8% (30/51) frequency for katG/Ser315 [37]. katG/Ser315Thr was found frequent in isoniazid resistant isolates in Belarus (100%), China (55%), Honduras (60%), Iran (40%), Romania (80%) [20], Nepal (62.2%) [43] and Poland (72%) [44]. As such, katG/Ser315Thr is a reliable target for rapid detection of isoniazid resistant M. tuberculosis irrespective of geographic location. However, significant variation by geographic region in its distribution has been reported [18]; for instance, of the 808 isoniazid resistant isolates from Japan and Korea, only 43% had katG/Ser315Thr [18]. In contrast, this mutation was observed in 94% of the 751 isoniazid resistant isolates from Eastern Europe. Importantly, sub-Saharan Africa was poorly represented in this analysis and a need for systematic surveys of regional patterns in mutations in the sub-continent was highlighted [18].

Furthermore, an isoniazid resistant isolate in this study had a frame shift mutation resulting from insertion of adenine at position 845 base pairs, which could have inactivated katG. Thus, isoniazid-resistance in this sole isolate with a frame shift mutation was probably due to deficiency of catalase peroxidase enzyme that activates isoniazid [6, 45, 46]. M. tuberculosis clinical isolates with deletion of the katG gene, which is required for catalase-peroxidase activation of isoniazid, were reported previously for two MDR-TB isolates in Uganda [37]. In addition, two isolates possessed katG/Asp406Ala, a mutation that substitutes a polar amino acid Aspartate with an aliphatic one, Alanine, which may lead to expression of a modified catalase peroxidase leading to insufficient isoniazid breakdown. The mutation Asp406Ala in katG has not been described in previous studies of isoniazid-resistant M. tuberculosis isolates in Uganda.

Within the inhA gene promoter, only 4 (8%) isoniazid-resistant isolates possessed the C (-15)T mutation. This finding is comparable with results of a study that reported a prevalence
of 5% for this mutation in MDR-TB isolates from Uganda [20]. The C(-15)T mutation is associated with low level resistance to isoniazid [47] and it occurs at lower frequencies compared to katG/Ser315Thr [6, 18]. Further, two isolates possessed T(-8)C, a mutation that is also associated with low level resistance to isoniazid. This mutation was reported previously in MDR-TB isolates from Uganda, Romania, Honduras, Iran, and Belarus, also at low frequencies [20]. Other inhA gene promoter mutations [A(-255)C, G(-116)A, A(-7)C, C(-8)A] occurred at much lower frequencies compared to C(-15)T and T(-8)C and this is consistent with findings from other investigators [18, 40], implying that isoniazid-resistance in Uganda is mostly attributable to the katG/Ser315Thr mutation. Indeed, majority (32, 78%) of the isoniazid-resistant isolates that lacked mutations in inhA gene promoter harboured katG/Ser315Thr, and they could still be detected by the rapid molecular assays as they target mutations both in katG and inhA promoter [47].

An unusual finding in this study was the relatively high prevalence of rifampicin- and isoniazid- resistant M. tuberculosis isolates that lacked resistance conferring mutations in rpoB/RRDR, katG and inhA promoter. However, similar findings were reported from other TB endemic countries [48, 49]. In fact, MDR-TB isolates that are phenotypically resistant to rifampicin (three isolates) and isoniazid (five isolates) but lacking resistance conferring mutations have already been reported in isolates from Uganda [37]. Yet, we have reported higher prevalence of those isolates in Uganda, implying they could prove to be problematic in the management of drug resistant TB patients. Further studies are required to fully characterize the molecular epidemiology of these isolates in Uganda, especially studies employing high throughput sequencing approaches to uncover all the potential resistance conferring mutations. Since the commercial rapid molecular assays for TB target only high confidence mutations to swiftly detect resistance to anti-TB drugs [31, 32, 42, 50], absence of targets is troublesome as it makes it nearly impossible to employ rapid molecular assays to detect certain resistant strains in clinical samples. On the other hand, strains that lacked mutations could harbour resistance conferring mutations in other genes e.g. ahpC, oxyR, kasA, furA and ndh that are associated with isoniazid-resistance [18, 51], or the use of efflux pumps for rifampicin-resistance [20, 25] but we did not investigate these mechanisms. Furthermore, although the resistant isolates that lacked known-resistance conferring mutations were validated as having no mutations, hetero-resistance due to mixed-strain resistant-plus-susceptible TB strains might have confounded the results, as both Sanger-DNA sequencing and rapid molecular assays (i.e. GeneXpert and LPAs) do not detect mixed-strain tuberculosis infections. In theory, mixed-strain tuberculosis infections can negatively impact the performance of rapid molecular tests for TB, especially in samples with hetero-resistant strains. Nevertheless, drug resistant strains lacking known resistance conferring mutations to rifampicin and isoniazid do occur [6], and our detection of these isolates is in agreement with several other global studies that described them [6, 18, 52–54].

Limitations
Our study focused on targeted Sanger-DNA sequencing of specific genes/loci associated with rifampicin and isoniazid resistant M. tuberculosis and this may not reveal all the possible mutations associated with rifampicin- and isoniazid-resistance. However, as a limited number of mutations is associated with resistance to rifampicin [6] and isoniazid [18], it is likely we covered the major mutations that confer resistance to these drugs in Uganda.

Conclusions
Sequence analysis of rpoB/RRDR, katG and inhA gene promoter is useful in the detection of rifampicin/isoniazid-resistant M. tuberculosis isolates in Uganda, and has revealed that drug
susceptible isolates in Uganda do not harbour mutations associated with resistance to rifampicin and isoniazid. The most prevalent high confidence mutation for rifampicin-resistance in Uganda is rpoB/Ser531Leu, although its frequency is low compared to estimates from other countries. Accordingly, a comparatively low frequency of high confidence mutations for rifampicin-resistance in M. tuberculosis sub-lineage Uganda strains explains their weak association with MDR-TB. Furthermore, katG/Ser315Thr is the most frequent high confidence mutation for isoniazid-resistance, and its frequency is comparable to estimates from other countries. Overall, a significant number (≤20%) of rifampicin/isoniazid-resistant isolates in Uganda lack high confidence resistance conferring mutations, implying that the commercial rapid molecular assays (e.g. Xpert MTB/RIF, Genotype MTBDRplus) will not detect them as resistant, potentially complicating the control of MDR-TB.

Materials and methods

Ethics approval
This study was approved by the Higher Degrees Research and Ethics Committee of Makerere University School of Biomedical Sciences. This committee authorized the use of archived M. tuberculosis isolates from adult patients ≥18 years who participated in the National and Kampala Drug Resistance Surveys that investigated phenotypic resistance to first- and second-line anti-TB drugs among new and previously treated TB cases in Uganda [55, 56]. Patient data was excluded from the characterized bacterial isolates however, the parent studies [55, 56] obtained written informed consent from the participants to participate in the study, and consent for sample storage and use of the stored sputum samples in further studies.

Study design and setting
This was a retrospective cross-sectional laboratory-based study conducted at the Molecular Biology Laboratory, Department of Immunology and Molecular Biology, Makerere University College of Health Sciences. The M. tuberculosis isolates investigated were collected during the recent Kampala and National TB Drug Resistance Surveys [55, 56]. Demographic data, sputum sample collection and culturing were described previously [55, 56]. Also, phenotypic drug susceptibility testing (DST) of the isolates was described previously [55, 56] but repeat testing was performed to validate the susceptibility patterns. As samples were taken from a nationwide cohort of new and previously treated sputum smear-positive TB patients registered at TB diagnostic centres in Uganda [55], the investigated isolates are representative of the entire country.

In the current study, we included 50 isoniazid-resistant isolates, 38 of which were also rifampicin-resistant (MDR isolates) while 12 were isoniazid-mono resistant. Additionally, 45 rifampicin-resistant isolates were studied, of which 38 were MDR while seven were rifampicin-resistant based on GeneXpert alone and lacked phenotypic DST data for isoniazid and rifampicin at the time of analysis. For quality control, 40 M. tuberculosis isolates that were fully susceptible to rifampicin, isoniazid and other first-line anti-TB drugs, were similarly investigated. Altogether, a total of 97 non-repetitive isolates (one isolate per patient) and a H37Rv laboratory strain were investigated.

Recovery and harvesting of the isolates
M. tuberculosis culturing and manipulation were performed in a BSL-3 Mycobacteriology Laboratory of the Dept. of Medical Microbiology, Makerere University College of Health Sciences. Briefly, the isolates were recovered by sub-culturing on Middlebrook 7H10 agar (Becton and Dickson, USA), incubating at 37°C in a CO₂ incubator (Thermal Scientific, USA), and
observing daily for growth of the organisms for 28 days. The cells were harvested and re-suspended in absolute ethanol (Sigma scientific, USA) to kill them by suffocation. The suspension was centrifuged at 16,000g to obtain the cell pellet that was later re-suspended in 0.25X Tris-EDTA (TE) buffer.

**Chromosomal DNA extraction**

High quality chromosomal DNA was extracted from *M. tuberculosis* by following the CTAB/chloroform extraction method [57]. Briefly, the cells, suspended in 0.25X TE buffer, were centrifuged at 3,000 g to wash off the media salts and residual ethanol. To lyse the cells, the cell pellet was re-suspended in 400 μL of freshly prepared 0.25X TE buffer, to which 50 μL of Lysozyme (40 mg/mL) was added and the mixture incubated at 37˚C, overnight. Then, 150μL of 10% SDS/Proteinase K solution was added to the mixture and incubated at 65˚C for 1 hour to ascertain complete cell lysis, precipitation of proteins and other cell debris. After this, 100μL of 5M NaCl was added to each tube followed by addition of 100μL of CTAB/NaCl and inverting the mixture several times until the content turned milky. To ensure complete precipitation of cell debris the solution was incubated at 65˚C for 10 min. To purify the DNA, 750 μL of Chloroform:Isoamyl alcohol mixture was added to the samples, followed by centrifugation at 16,000 g for 10 min. After this, the aqueous phase that contained the DNA was carefully transferred to a pre-labelled sterile 1.5ml centrifuge tube (Eppendorf Inc.), to which 600μL of absolute ice cold isopropanol (Fisher Scientific, USA) was added to precipitate the genomic DNA. After incubating at -20˚C for 2 hours, the mixture was centrifuged for 10 min at 16,000 g to pellet the DNA. The pellet was washed with 1ml of 70% ice-cold ethanol and dried at room temperature for 1 hour. The DNA was eluted in 50 μL of 0.25X TE buffer. Prior to use as template in PCRs the quality and quantity of the extracted DNA was determined by electrophoresis on a 1% agarose gel and a NanoDrop spectrophotometer (ThermoFisher Scientific).

**Genotyping**

Isolates were confirmed as belonging to the *M. tuberculosis* complex (MTBC) by using an in-house PCR protocol described previously [58], in which they all tested positive for the insertion sequence IS6110 confirmatory for MTBC. Furthermore, 15 loci Mycobacterial Interspersed Repetitive Units-Variable Number of Tandem Repeats (MIRU-VNTR) analysis was performed as described previously [59] to determine the *M. tuberculosis* genotypes/sub-lineages.

**PCR, DNA-sequencing and analysis**

We used previously published gene/locus specific primers and procedures to amplify specific fragments of rifampicin- and isoniazid-resistance associated genes/loci (i.e. rpoB, katG, inhA gene promoter) from *M. tuberculosis* [6, 20]. The total reaction volume was 60μL, prepared according to the HotStar PCR kit protocol (Qiagen, Hilden, Germany). Briefly, each reaction contained 27.5μL nuclease free water, 6μL 10x PCR buffer, 12μL Q-solution, 3μL 10mM MgCl2, 3μL 10mM dNTPs, 1.5μL each of reverse and forward primers, 0.5μL High fidelity Taq DNA polymerase (5U/μL) (Sigma-Aldrich, USA), and 10ng/μL (in 5μL volume) chromosomal DNA template. Amplification was achieved in a BioRad T100 Thermal cycler (Bio-Rad Laboratories Inc., Singapore) using the following program: initial denaturation at 95˚C, 5 min followed by 35 cycles each consisting of 95˚C, 45 sec; 60˚C, 45 sec; and 72˚C, 50 sec with a final extension step of 72˚C, 10 min. Five microliters each of the PCR product was analysed on a 1% agarose gel stained with ethidium bromide (0.5 μg/ml). Gels were run at 120V for 1 hour and
visualized using a UVP Gel documentation (Benchtop Trans-illuminator System_BioDoc-it, CA, USA).

Furthermore, 50μL each of the PCR products was purified with the QIAmp DNA purification mini kit (Qiagen, Hilden, Germany), and the purified amplicons sequenced at ACGT Inc. (Wheeling IL, USA). The sequences we obtained (S2 Fig) were analysed first through BLAST searching at NCBI https://blast.ncbi.nlm.nih.gov/Blast.cgi to confirm they hit the expected gene sequences in *M. tuberculosis*. Poor quality bases at the beginning and end of the sequences were trimmed off. To determine the amino acid substitutions, DNA sequences were translated into amino acid sequences using the Molecular Evolutionary Genetics Analysis Version 6.0 (MEGA6.06) software [60] or the ExPASy-Translate server http://web.expasy.org/translate/. To determine presence/absence of mutations in the sequenced genes/loci, the curated sequences were aligned using MEGA6.06 (or BioEdit v7.2.5.0) to sequences of *rpoB*, *katG*, and *inhA* gene promoter obtained from the genome sequence of *M. tuberculosis* strain H37Rv (NCBI reference sequence NC_000962). To determine whether the identified mutations were resistance conferring, we used tbdream database [27] https://tbdreamdb.ki.se/Info/ and published literature [6, 18, 61, 62]. The data was curated, compiled and presented as tables or percentages depending on frequencies of mutations that occurred in the examined genes/loci (S1 Table). The Chi-square test was used to evaluate the associations between *M. tuberculosis* lineages, sub-lineages/genotypes and drug-resistance conferring mutations.

**Quality control**

The *M. tuberculosis* laboratory strain H37Rv is susceptible to all anti-TB drugs and it was used as the wild-type in determining resistance-conferring mutations. Additionally, a known MDR-TB strain with well-characterized rifampicin/isoniazid-resistance conferring mutations was included as the positive control for resistance mutations. Negative controls for DNA extraction and PCRs were included to rule out contamination. High-Fidelity Taq DNA polymerase (Sigma-Aldrich, USA) that delivers superior results with twofold higher yield and threefold greater fidelity compared to regular Taq Polymerases was used in all the PCRs. All sequenced amplicons were confirmed through nucleotide-BLAST, translated-BLAST, and protein-BLAST analysis and they all hit the expected genes/loci in *M. tuberculosis*.

**Supporting information**

**S1 Table.** Characteristics of rifampicin and isoniazid resistant *M. tuberculosis* isolates investigated.

(XLSX)

**S1 Fig.** Panels A and B, genotypes/sub-lineages of *M. tuberculosis* isolates resistant to isoniazid and rifampicin, respectively.

(TIFF)

**S2 Fig.** Selected chromatograms for sequenced *rpoB*, *katG* and *inhA* gene promoter fragments from rifampicin/isoniazid resistant *M. tuberculosis* isolates. Codons of interest are circled. Panels: A, positive control (rifampicin-susceptible isolate) with wild-type codon TCG (encodes Serine at nucleotide position 531 of *rpoB*/RRDR; B, rifampicin-resistant isolate showing a transition at codon 531 in *rpoB*/RRDR that altered TCG to TTG (encodes Leucine), the most prevalent high confidence mutation (Ser531Leu) for rifampicin resistance; C & D, isoniazid-susceptible and isoniazid-resistant isolates, respectively, showing transversion (for resistant isolates) at *katG*/315 (AGC to ACC) that substituted Serine for Threonine hence the frequent high confidence mutation *katG*/Ser315Thr; E & F, isoniazid-susceptible and
isoniazid-resistant isolates, respectively, showing mutation of C to T (resistant isolates) in \textit{inhA} gene promoter at nucleotide position -15.

\section*{Acknowledgments}

This work was supported in part by the “Basic HIV and HIV/AIDS-Related Diseases Science Training Program for Uganda (BHSTP)” funded by Fogarty International Center (grant# ID43TW009780). The work was also supported through a DELTAS Africa Initiative [grant# 107743/Z/15/Z]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA), and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant no. 107743) and the UK Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We thank staff at the National Tuberculosis Reference Laboratory/SRL Uganda for technical assistance. For administrative support, we thank Justine Nakibuuka (Uganda-Case Western Research Collaboration), Ivan Mwebaza, Joan Basemera, Carolyne Atugonza, Peter Katumba, Moses Okee, & Geraldine Nalwadda (Makerere University College of Health Sciences); Joshua Mandre & Allen Mukhwana (MUII-plus, Entebbe).

\section*{Author Contributions}

\textbf{Conceptualization:} David Patrick Kateete.

\textbf{Data curation:} George W. Kasule, Kenneth Musisi, David Patrick Kateete.

\textbf{Formal analysis:} Edgar Kigozi, David Patrick Kateete.

\textbf{Funding acquisition:} Moses L. Joloba, David Patrick Kateete.

\textbf{Investigation:} George W. Kasule, Deus Lukoye, Moses L. Joloba, David Patrick Kateete.

\textbf{Methodology:} Edgar Kigozi, Deus Lukoye, Fred Ashaba Katabazi, David Patrick Kateete.

\textbf{Project administration:} David Patrick Kateete.

\textbf{Resources:} Kenneth Musisi, Samuel Kyobe, Moses L. Joloba, David Patrick Kateete.

\textbf{Software:} Edgar Kigozi, David Patrick Kateete.

\textbf{Supervision:} Eddie M. Wampande, Moses L. Joloba, David Patrick Kateete.

\textbf{Validation:} Edgar Kigozi, David Patrick Kateete.

\textbf{Visualization:} Edgar Kigozi.

\textbf{Writing – original draft:} Edgar Kigozi, David Patrick Kateete.

\textbf{Writing – review \\& editing:} David Patrick Kateete.

\section*{References}

1. Lange C, Abubakar I, Alffenaar J-WC, Bothamley G, Caminero JA, Carvalho ACC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. The European Respiratory Journal. 2014; 44(1):23–63. https://doi.org/10.1183/09031936.00188313 PubMed PMID: PMC4076529. PMID: 24659544

2. Lawn SD, Zumla A. Tuberculosis. Lancet (London, England). 2011; 378(9785):57–72. Epub 2011/03/23. https://doi.org/10.1016/s0140-6736(10)62173-3 PMID: 21420161.
Bazira J, Asiimwe BB, Joloba ML, Bwanga F, Matee MI. Use of the GenoType(R) MTBDRplus assay to

Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, et al. Rapid screening of MDR-

Walusimbi S, Bwanga F, Costa AD, Haile M, Hoffner S, Joloba M. Evaluation of the Xpert(R) MTB/Rif
diagnostic study. BMC infectious diseases. 2013; 13:133. Epub 2013/09/01. https://doi.org/10.1186/

Ssengoba W, Nakiyingi L, Armstrong DT, Cobelens FG, Alland D, Manabe YC, et al. Clinical utility of a

Feuerriegel S, Koser CU, Niemann S. Phylogenetic polymorphisms in antibiotic resistance genes of the

Koser CU, Bryant JM, Becq J, Torok ME, Ellington MJ, Marti-Renom MA, et al. Whole-genome

Susceptibility Testing of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2011;

Sekadde MP, Wobudeya E, Joloba ML, Ssengoba W, Kisembo H, Bakeera-Kitaka S, et al. Evaluation of the Xpert(R) MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study. BMC infectious diseases. 2013; 13:133. Epub 2013/03/19. https://doi.org/10.1186/1471-2334-13-133 PMID: 23497044; PubMed Central PMCID: PMCPmc3602671.

Nakiyingi L, Nankabiwa H, Lamorde M. Tuberculosis diagnosis in resource-limited settings: Clinical

WHO. The top 10 causes of death http://www.who.int/mediacentre/factsheets/fs310/en/ [updated

WHO. Tuberculosis http://www.who.int/mediacentre/factsheets/fs104/en/ 2017 [updated March

WHO. The top 10 causes of death http://www.who.int/mediacentre/factsheets/fs310/en/ 2017 [updated

WHO. Leading causes of death by economy income group http://www.who.int/mediacentre/factsheets/

McIvor A, Koornhof H, Kana BD. Relapse, re-infection and mixed infections in tuberculosis disease. Pathogens and Disease. 2017; 75(3):ftx020-ftx. https://doi.org/10.1093/femspd/ftx020 PMID: 28334088

Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review. PloS one. 2015; 10(3):e0119628. https://doi.org/10.1371/journal.pone.0119628 PubMed PMID: PMC4370653. PMID: 25799046

Brites D, Gagneux S. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunological Reviews. 2015; 264(1):6–24. https://doi.org/10.1111/imr.12264 PubMed PMID: PMC4339235. PMID: 25703549

Rosales-Klintz S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, et al. Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.

WHO. Leading causes of death by economy income group http://www.who.int/mediacentre/factsheets/

WHO. The top 10 causes of death http://www.who.int/mediacentre/factsheets/fs310/en/ 2017 [updated

McIvor A, Koornhof H, Kana BD. Relapse, re-infection and mixed infections in tuberculosis disease. Pathogens and Disease. 2017; 75(3):ftx020-ftx. https://doi.org/10.1093/femspd/ftx020 PMID: 28334088

Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review. PloS one. 2015; 10(3):e0119628. https://doi.org/10.1371/journal.pone.0119628 PubMed PMID: PMC4370653. PMID: 25799046

Brites D, Gagneux S. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunological Reviews. 2015; 264(1):6–24. https://doi.org/10.1111/imr.12264 PubMed PMID: PMC4339235. PMID: 25703549

Rosales-Klintz S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, et al. Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.

WHO. The top 10 causes of death http://www.who.int/mediacentre/factsheets/fs310/en/ 2017 [updated

WHO. Tuberculosis http://www.who.int/mediacentre/factsheets/fs104/en/ 2017 [updated March

WHO. The top 10 causes of death http://www.who.int/mediacentre/factsheets/fs310/en/ 2017 [updated

WHO. Leading causes of death by economy income group http://www.who.int/mediacentre/factsheets/

McIvor A, Koornhof H, Kana BD. Relapse, re-infection and mixed infections in tuberculosis disease. Pathogens and Disease. 2017; 75(3):ftx020-ftx. https://doi.org/10.1093/femspd/ftx020 PMID: 28334088

Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review. PloS one. 2015; 10(3):e0119628. https://doi.org/10.1371/journal.pone.0119628 PubMed PMID: PMC4370653. PMID: 25799046

Brites D, Gagneux S. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunological Reviews. 2015; 264(1):6–24. https://doi.org/10.1111/imr.12264 PubMed PMID: PMC4339235. PMID: 25703549

Rosales-Klintz S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, et al. Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.
Matsioti-Bernard P, Vrioni G, Marinis E. Characterization of rpoB mutations in rifampin-resistant clinical isolates from Uganda. International journal of mycobacteriology. 2012; 1(3):124–30. Epub 2012/09/01. https://doi.org/10.1016/j.ijmyco.2012.08.001 PMID: 22787207.

21. Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, et al. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nature genetics. 2016; 48(12):1535–43. https://doi.org/10.1038/ng.3704 PMID: 27798628.

22. Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, et al. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdiagnosis of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. PLoS one. 2014; 9(4):e95083. Epub 2014/04/20. https://doi.org/10.1371/journal.pone.0095083 PMID: 24743770; PubMed Central PMCID: PMC3990612.

23. Chakravorty S, Xie YL, Dorman SE. Molecular Drug-Susceptibility Test for Tuberculosis. The New England journal of medicine. 2017; 377(24):2404. Epub 2017/12/14. https://doi.org/10.1056/NEJMct1714218 PMID: 29236631.

24. Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, et al. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. The New England journal of medicine. 2017; 377(11):1043–54. Epub 2017/09/14. https://doi.org/10.1056/NEJMoa1614915 PMID: 28902596; PubMed Central PMCID: PMC5727572.

25. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. Study of the Rifampin Monoresistance Mechanism in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2013; 57(2):893–900. https://doi.org/10.1128/AAC.01024-12 PMID: 23208715

26. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2004; 48(4):1289–94. https://doi.org/10.1128/AAC.48.4.1289-1294.2004 PMID: PMC375340. PMID: 15047531

27. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis Drug Resistance Mutation Database. PLoS Medicine. 2009; 6(2):e1000002. https://doi.org/10.1371/journal.pmed.1000002 PubMed PMID: PMC2637921. PMID: 19209951

28. Ezati N, Lukoye D, Wampande EM, Musisi K, Kasule GW, Cobelens FGJ, et al. The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda. BMC infectious diseases. 2014; 14:703. https://doi.org/10.1186/s12879-014-0703-0 PubMed PMID: 25253472

29. Lukoye D, Katabazi FA, Musisi K, Kateete DP, Asimwe BB, Okeke M, et al. The T2 Mycobacterium tuberculosis genotype, predominant in Kampala, Uganda, shows negative correlation with antituberculosis drug resistance. Antimicrob Agents Chemother. 2014; 58(7):3853–9. Epub 2014/04/30. https://doi.org/10.1128/AAC.02338-13 PMID: 24777100; PubMed Central PMCID: PMCPmc4068514.

30. Shubladze N, Tadumadze N, Babilshvili N. Molecular patterns of multidrug resistance of Mycobacterium tuberculosis in Georgia. International journal of mycobacteriology. 2013; 2(2):73–8. https://doi.org/10.1016/j.ijmyco.2013.02.002 PMID: 24904758

31. Ramaswamy SV, Dou S-J, Rendon A, Yang Z, Cave MD, Graviss EA. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico. Journal of medical microbiology. 2004; 53(2):107–13.

32. Qazi O, Rahman H, Tahir Z, Qasim M, Khan S, Anjum AA, et al. Mutation pattern in rifampicin resistant Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda. BMC infectious diseases. 2014; 14:703. https://doi.org/10.1186/s12879-014-0703-0 PubMed PMID: 24904758

33. Tracesvska T, Jansone I, Broka L, Marga O, Baumanis V. Mutations in the rpoB and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia. Journal of clinical microbiology. 2002; 40(10):3789–92. https://doi.org/10.1128/JCM.40.10.3789-3792.2002 PMID: 12354882

34. Jou R, Chen H-Y, Chiang C-Y, Yu M-C, Su I-J. Genetic diversity of multidrug-resistant Mycobacterium tuberculosis isolates and identification of 11 novel rpoB alleles in Taiwan. Journal of clinical microbiology. 2005; 43(3):1390–4. https://doi.org/10.1128/JCM.43.3.1390-1394.2005 PMID: 15750115

35. Matsioti-Bernard P, Vrioni G, Marinis E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosisisolates from Greece. Journal of clinical microbiology. 1998; 36(1):20–3. PMID: 9431913

36. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrobial agents and chemotherapy. 1996; 40(4):1053–6. PMID: 8849230

37. Clark TG, Mallard K, Coll F, Preston M, Assefa S, Harris D, et al. Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing.
38. Herrera L, Jiménez S, Valverde A, García MA, Sáez-Nieto JA. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996–2001). Description of new mutations in the rpoB gene and review of the literature. International journal of antimicrobial agents. 2003; 21(5):403–8. PMID: 12727071

39. Hauck Y, Fabre M, Vergnaud G, Soler C, Pourcel C. Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. Journal of antimicrobial chemotherapy. 2009:dkp204.

40. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle and Lung disease. 1998; 79(1):3–29. https://doi.org/10.1054/tuld.1998.0002 PMID: 10645439

41. Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, et al. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. Journal of clinical microbiology. 2015; 53(5):1473–83. https://doi.org/10.1128/JCM.02993-14 PMID: 25673793

42. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, et al. Rapid antibiotic resistance predictions from genome sequence data for S. aureus and M. tuberculosis. BioRxiv. 2015:018564.

43. Marahatta S, Gautam S, Dhital S, Pote N, Jha A, Mahoto R, et al. katG (SER 315 THR) Gene Mutation in isoniazid resistant Mycobacterium tuberculosis. Kathmandu University Medical Journal. 2012; 9(1):19–23.

44. Jagielski T, Bakula Z, Roeske K, Kamiński M, Napíorkowska A, Augustynowicz-Kopiec E, et al. Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates. Journal of Antimicrobial Chemotherapy. 2014:dku161.

45. Makeshkumar Veluchamy RM, Narayanan Sujatha, Rajesh Lakshmi. katG gene as a surrogate molecular marker leading to cause Drug resistance in Mycobacterium tuberculosis isolates American Journal of Infectious diseases and Microbiology. 2013; 1(5):86–91. Epub 91.

46. Rozwarski DA, Barton DHR et al. Modification of the NADH of the Isoniazid target (inhA) from Mycobacterium tuberculosis. Journal of Science. 1998; 279:98–102. Epub 102.

47. Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High Prevalence of inh A Promoter Mutation among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. PloS one. 2015; 10(9):e0135003. https://doi.org/10.1371/journal.pone.0135003 PMID: 26332235

48. Poudel A, et al. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal. Antimicrobial agents and chemotherapy. 2012; 56(6):2831–6. https://doi.org/10.1128/AAC.06418-11 PMID: 22450970

49. Tekwu EM, Sidze LK, Assam J-PA, Tedom J-C, Tchatchouang S, Makafe GG, et al. Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon. BMC Microbiology. 2014; 14(1):113. https://doi.org/10.1186/1471-2180-14-113 PMID: 24884632

50. Maurya A, Singh A, Kant S, Umarao J, Kumar M, Kushwaha R, et al. Use of GenoType® MTBDRplus assay to assess drug resistance and mutation patterns of multidrug-resistant tuberculosis isolates in northern India. Indian journal of medical microbiology. 2013; 31(3):230. https://doi.org/10.4103/0255-0857.115625 PMID: 23893707

51. Tekwu EM, Sidze LK, Assam J-PA, Tedom J-C, Tchatchouang S, Makafe GG, et al. Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon. BMC microbiology. 2014; 14(1):1.

52. Kapur V, Li L-L, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN, et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. Journal of clinical microbiology. 1994; 32(4):1095–8. PMID: 8027320

53. Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol. 2001; 39(8):2987–90. Epub 2001/07/28. https://doi.org/10.1128/JCM.39.8.2987-2990.2001 PMID: 11474030; PubMed Central PMCID: PMC992777.

54. Poudel A, Nakajima C, Fukushima Y, Suzuki H, Pandey BD, Maharjan B, et al. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal. Antimicrob Agents Chemother. 2012; 56(6):2831–6. Epub 2012/03/28. https://doi.org/10.1128/AAC.06418-11 PMID: 22450970; PubMed Central PMCID: PMCPmc3570716.

55. Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, et al. Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis Patients in Uganda: Results
of the First National Survey. PLoS one. 2013; 8(8):e70763. https://doi.org/10.1371/journal.pone.0070763 PMID: 23936467

56. Lukoye D, Cobelens FGJ, Ezati N, Kirimunda S, Adatu FE, Lule JK, et al. Rates of Anti-Tuberculosis Drug Resistance in Kampala-Uganda Are Low and Not Associated with HIV Infection. PLoS one. 2011; 6(1):e16130. https://doi.org/10.1371/journal.pone.0016130 PMID: 21249225

57. van Helden PD, Victor TC, Warren RM, van Helden EG. Isolation of DNA from Mycobacterium tuberculosis. In: Parish T, Stoker NG, editors. Mycobacterium tuberculosis Protocols. Totowa, NJ: Humana Press; 2001. p. 19–30.

58. Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi P, Whalen C, Mugerwa RD, et al. Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. The International Journal of Tuberculosis and Lung Disease. 2006; 10(11):1262–7. PMID: 17131786

59. Nabyonga L, Kateete DP, Katabazi FA, Odong PR, Whalen CC, Dickman KR, et al. Determination of circulating Mycobacterium tuberculosis strains and transmission patterns among pulmonary TB patients in Kawempe municipality, Uganda, using MIRU-VNTR. BMC research notes. 2011; 4:280. Epub 2011/08/13. https://doi.org/10.1186/1756-0500-4-280 PMID: 21835016; PubMed Central PMCID: PMCPmc3162915.

60. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Molecular biology and evolution. 2013; 30(12):2725–9. Epub 2013/10/18. https://doi.org/10.1093/molbev/mst197 PMID: 24132122; PubMed Central PMCID: PMCPmc3840312.

61. Engström A, Morcillo N, Imperiale B, Hoffner SE, Jurén P. Detection of First- and Second-Line Drug Resistance in Mycobacterium tuberculosis Clinical Isolates by Pyrosequencing. Journal of Clinical Microbiology. 2012; 50(6):2026–33. https://doi.org/10.1128/JCM.00664-11 PubMed PMID: PMCPmc3372151. PMID: 22461677

62. Huyen MNT, Cobelens FGJ, Buu TN, Lan NTN, Dung NH, Kremer K, et al. Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes. Antimicrobial Agents and Chemotherapy. 2013; 57(6):3620–7. https://doi.org/10.1128/AAC.00077-13 PubMed PMID: PMCPmc3719713. PMID: 23669727